A monocytic detour to replicate patient‐derived hepatitis C virus in hepatoma cells and its use for phenotypic analyses
Laurent Chatel‐Chaix, Ralf Bartenschlager – 21 November 2014
Cre‐ativity in the liver: Transgenic approaches to targeting hepatic nonparenchymal cells
Stephen N. Greenhalgh, Kylie P. Conroy, Neil C. Henderson – 21 November 2014 – Rapid evolution in transgenic (Tg) mouse technology now permits cell‐specific and temporal control of fluorescent cell‐labeling and gene inactivation. Here, we discuss the principal strategies that have been utilized to target, label, and manipulate hepatic nonparenchymal cells, with emphasis on the utility of constitutive and inducible Cre‐lox systems.
Development of risk scoring system for stratifying population for hepatocellular carcinoma screening
Yi‐Chun Hung, Chih‐Lin Lin, Chun‐Jen Liu, Hung Hung, Shi‐Ming Lin, Shou‐Dong Lee, Pei‐Jer Chen, Shu‐Chun Chuang, Ming‐Whei Yu – 21 November 2014 – The age and risk level that warrants hepatocellular carcinoma (HCC) screening remains to be defined. To develop risk scores for stratifying average‐risk population for mass HCC screening, we conducted a pooled analysis using data from three cohorts involving 12,377 Taiwanese adults 20‐80 years of age. During 191,240.3 person‐years of follow‐up, 387 HCCs occurred.
Transarterial chemoembolization and radiological vascular complications
Fabrizio Panaro, Boris Guiu, Francis Navarro – 19 November 2014
Cardiac tamponade following liver transplantation after intrapericardial control of the suprahepatic vena cava
Junming Xu, Johnny C. Hong, Ronald W. Busuttil – 19 November 2014 – Transabdominal intrapericardial control of the suprahepatic inferior vena cava (SIVC) is a rather uncommon procedure occasionally required in conjunction with complicated liver transplantation (LT) and hepatobiliary surgery. Experience with this technique is limited. Here we report 6 cases of LT in which transabdominal intrapericardial control of the SIVC was necessary.
Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?
Carla Silva, Elizabeth Ianna, Tracey Jones, Joshua S. Davis – 7 November 2014
Transforming growth factor‐β–induced long noncoding RNA promotes liver cancer metastasis via RNA–RNA crosstalk
Tingting Sun, Nathalie Wong – 7 November 2014
The case for cost‐effectively treating cryoglobulinemic vasculitis with interferon‐free anti–hepatitis C virus therapy
Marcella Visentini, Stefania Colantuono, Guido Granata, Adriano de Santis, Massimo Fiorilli, Milvia Casato – 7 November 2014
Hepatic artery stenosis after liver transplantation: Is endovascular treatment always necessary?
Carlo Pulitano, David Joseph, Charbel Sandroussi, Deborah Verran, Simone I. Strasser, Nicholas A. Shackel, Geoffrey W. McCaughan, Michael Crawford – 6 November 2014 – Hepatic artery stenosis (HAS) is thought to predispose patients to biliary complications secondary to ischemic injury. Despite this, the clinical significance of HAS remains poorly defined. The aims of this study were to determine the prevalence and outcomes of HAS and to define which patients might benefit from endovascular treatment.
Is the Molecular Adsorbent Recirculating System the Answer for Children With Acute Liver Failure?
Philip Rosenthal – 6 November 2014